nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—CYP1A1—head and neck cancer	0.646	1	CbGaD
Riluzole—ABCG2—Fluorouracil—head and neck cancer	0.0913	0.46	CbGbCtD
Riluzole—ABCG2—Docetaxel—head and neck cancer	0.0697	0.351	CbGbCtD
Riluzole—CYP1A2—Fluorouracil—head and neck cancer	0.0376	0.19	CbGbCtD
Riluzole—SLC7A11—forelimb zeugopod—head and neck cancer	0.0161	0.503	CbGeAlD
Riluzole—SLC7A11—tongue—head and neck cancer	0.00433	0.135	CbGeAlD
Riluzole—SLC7A11—mouth—head and neck cancer	0.00291	0.091	CbGeAlD
Riluzole—SLC7A11—thyroid gland—head and neck cancer	0.00118	0.037	CbGeAlD
Riluzole—SLC7A11—head—head and neck cancer	0.00105	0.0328	CbGeAlD
Riluzole—CYP1A1—mouth—head and neck cancer	0.000909	0.0284	CbGeAlD
Riluzole—ABCG2—parotid gland—head and neck cancer	0.000667	0.0209	CbGeAlD
Riluzole—ABCG2—saliva-secreting gland—head and neck cancer	0.000639	0.02	CbGeAlD
Riluzole—CYP1A1—parotid gland—head and neck cancer	0.000633	0.0198	CbGeAlD
Riluzole—SCN5A—head—head and neck cancer	0.000632	0.0198	CbGeAlD
Riluzole—CYP1A1—epithelium—head and neck cancer	0.000529	0.0165	CbGeAlD
Riluzole—CYP1A1—trachea—head and neck cancer	0.000468	0.0146	CbGeAlD
Riluzole—Haemorrhage—Vinblastine—head and neck cancer	0.000464	0.00387	CcSEcCtD
Riluzole—Blood bilirubin increased—Docetaxel—head and neck cancer	0.000463	0.00386	CcSEcCtD
Riluzole—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000462	0.00386	CcSEcCtD
Riluzole—Hypoaesthesia—Vinblastine—head and neck cancer	0.000462	0.00385	CcSEcCtD
Riluzole—Pharyngitis—Vinblastine—head and neck cancer	0.000461	0.00384	CcSEcCtD
Riluzole—Stomatitis—Hydroxyurea—head and neck cancer	0.00046	0.00384	CcSEcCtD
Riluzole—Cardiac failure—Fluorouracil—head and neck cancer	0.000451	0.00377	CcSEcCtD
Riluzole—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000446	0.00372	CcSEcCtD
Riluzole—Respiratory failure—Docetaxel—head and neck cancer	0.000446	0.00372	CcSEcCtD
Riluzole—Osteoarthritis—Fluorouracil—head and neck cancer	0.00044	0.00368	CcSEcCtD
Riluzole—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00044	0.00368	CcSEcCtD
Riluzole—Hepatocellular injury—Docetaxel—head and neck cancer	0.000438	0.00365	CcSEcCtD
Riluzole—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000438	0.00365	CcSEcCtD
Riluzole—Pulmonary embolism—Docetaxel—head and neck cancer	0.000438	0.00365	CcSEcCtD
Riluzole—Injection site reaction—Docetaxel—head and neck cancer	0.000435	0.00363	CcSEcCtD
Riluzole—Haemoglobin—Hydroxyurea—head and neck cancer	0.000425	0.00355	CcSEcCtD
Riluzole—Haemorrhage—Hydroxyurea—head and neck cancer	0.000423	0.00353	CcSEcCtD
Riluzole—Hallucination—Hydroxyurea—head and neck cancer	0.000421	0.00352	CcSEcCtD
Riluzole—Cardiac arrest—Fluorouracil—head and neck cancer	0.000419	0.0035	CcSEcCtD
Riluzole—Candida infection—Docetaxel—head and neck cancer	0.000418	0.00349	CcSEcCtD
Riluzole—Fluid retention—Docetaxel—head and neck cancer	0.000416	0.00347	CcSEcCtD
Riluzole—Ataxia—Fluorouracil—head and neck cancer	0.000414	0.00346	CcSEcCtD
Riluzole—Alopecia—Vinblastine—head and neck cancer	0.00041	0.00342	CcSEcCtD
Riluzole—Neoplasm—Docetaxel—head and neck cancer	0.000396	0.0033	CcSEcCtD
Riluzole—Pulmonary oedema—Docetaxel—head and neck cancer	0.00039	0.00325	CcSEcCtD
Riluzole—ABCG2—thyroid gland—head and neck cancer	0.00039	0.0122	CbGeAlD
Riluzole—Muscular weakness—Fluorouracil—head and neck cancer	0.000388	0.00324	CcSEcCtD
Riluzole—Angiopathy—Hydroxyurea—head and neck cancer	0.000384	0.00321	CcSEcCtD
Riluzole—Dysphagia—Fluorouracil—head and neck cancer	0.000381	0.00318	CcSEcCtD
Riluzole—Sepsis—Docetaxel—head and neck cancer	0.00038	0.00317	CcSEcCtD
Riluzole—Chills—Hydroxyurea—head and neck cancer	0.00038	0.00317	CcSEcCtD
Riluzole—CYP1A2—thyroid gland—head and neck cancer	0.000375	0.0117	CbGeAlD
Riluzole—Ill-defined disorder—Vinblastine—head and neck cancer	0.000375	0.00313	CcSEcCtD
Riluzole—Alopecia—Hydroxyurea—head and neck cancer	0.000374	0.00312	CcSEcCtD
Riluzole—Anaemia—Vinblastine—head and neck cancer	0.000374	0.00312	CcSEcCtD
Riluzole—Angina pectoris—Fluorouracil—head and neck cancer	0.000371	0.00309	CcSEcCtD
Riluzole—CYP1A1—thyroid gland—head and neck cancer	0.00037	0.0116	CbGeAlD
Riluzole—Phlebitis—Docetaxel—head and neck cancer	0.000369	0.00308	CcSEcCtD
Riluzole—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000366	0.00305	CcSEcCtD
Riluzole—Malaise—Vinblastine—head and neck cancer	0.000364	0.00304	CcSEcCtD
Riluzole—Vertigo—Vinblastine—head and neck cancer	0.000363	0.00303	CcSEcCtD
Riluzole—Leukopenia—Vinblastine—head and neck cancer	0.000362	0.00302	CcSEcCtD
Riluzole—Pancytopenia—Fluorouracil—head and neck cancer	0.000362	0.00302	CcSEcCtD
Riluzole—Deafness—Docetaxel—head and neck cancer	0.000355	0.00297	CcSEcCtD
Riluzole—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000351	0.00293	CcSEcCtD
Riluzole—Convulsion—Vinblastine—head and neck cancer	0.00035	0.00292	CcSEcCtD
Riluzole—Hypertension—Vinblastine—head and neck cancer	0.000349	0.00291	CcSEcCtD
Riluzole—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000347	0.0029	CcSEcCtD
Riluzole—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000342	0.00285	CcSEcCtD
Riluzole—Pneumonia—Fluorouracil—head and neck cancer	0.000341	0.00285	CcSEcCtD
Riluzole—Anaemia—Hydroxyurea—head and neck cancer	0.000341	0.00284	CcSEcCtD
Riluzole—Discomfort—Vinblastine—head and neck cancer	0.00034	0.00284	CcSEcCtD
Riluzole—Infestation NOS—Fluorouracil—head and neck cancer	0.000339	0.00283	CcSEcCtD
Riluzole—Infestation—Fluorouracil—head and neck cancer	0.000339	0.00283	CcSEcCtD
Riluzole—Atrial fibrillation—Docetaxel—head and neck cancer	0.000335	0.0028	CcSEcCtD
Riluzole—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000335	0.00279	CcSEcCtD
Riluzole—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000333	0.00278	CcSEcCtD
Riluzole—Myocardial infarction—Fluorouracil—head and neck cancer	0.000333	0.00278	CcSEcCtD
Riluzole—Malaise—Hydroxyurea—head and neck cancer	0.000332	0.00277	CcSEcCtD
Riluzole—Stomatitis—Fluorouracil—head and neck cancer	0.000331	0.00276	CcSEcCtD
Riluzole—Urinary tract infection—Fluorouracil—head and neck cancer	0.00033	0.00275	CcSEcCtD
Riluzole—Leukopenia—Hydroxyurea—head and neck cancer	0.00033	0.00275	CcSEcCtD
Riluzole—CYP1A1—head—head and neck cancer	0.000328	0.0103	CbGeAlD
Riluzole—Cardiac failure—Docetaxel—head and neck cancer	0.000326	0.00272	CcSEcCtD
Riluzole—Thrombocytopenia—Vinblastine—head and neck cancer	0.000323	0.00269	CcSEcCtD
Riluzole—Epistaxis—Fluorouracil—head and neck cancer	0.00032	0.00267	CcSEcCtD
Riluzole—Convulsion—Hydroxyurea—head and neck cancer	0.000319	0.00266	CcSEcCtD
Riluzole—Hyponatraemia—Docetaxel—head and neck cancer	0.000319	0.00266	CcSEcCtD
Riluzole—Sinusitis—Fluorouracil—head and neck cancer	0.000318	0.00266	CcSEcCtD
Riluzole—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000318	0.00265	CcSEcCtD
Riluzole—Agranulocytosis—Fluorouracil—head and neck cancer	0.000317	0.00264	CcSEcCtD
Riluzole—Anorexia—Vinblastine—head and neck cancer	0.000314	0.00262	CcSEcCtD
Riluzole—Migraine—Docetaxel—head and neck cancer	0.000313	0.00261	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000312	0.0026	CcSEcCtD
Riluzole—Discomfort—Hydroxyurea—head and neck cancer	0.00031	0.00259	CcSEcCtD
Riluzole—Haemoglobin—Fluorouracil—head and neck cancer	0.000306	0.00256	CcSEcCtD
Riluzole—Rhinitis—Fluorouracil—head and neck cancer	0.000305	0.00255	CcSEcCtD
Riluzole—Haemorrhage—Fluorouracil—head and neck cancer	0.000305	0.00254	CcSEcCtD
Riluzole—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000303	0.00253	CcSEcCtD
Riluzole—Pharyngitis—Fluorouracil—head and neck cancer	0.000302	0.00252	CcSEcCtD
Riluzole—CYP1A2—Arylamine metabolism—NAT2—head and neck cancer	0.000301	0.0743	CbGpPWpGaD
Riluzole—Oedema—Hydroxyurea—head and neck cancer	0.000301	0.00251	CcSEcCtD
Riluzole—Ataxia—Docetaxel—head and neck cancer	0.000299	0.00249	CcSEcCtD
Riluzole—Infection—Hydroxyurea—head and neck cancer	0.000299	0.00249	CcSEcCtD
Riluzole—Paraesthesia—Vinblastine—head and neck cancer	0.000296	0.00247	CcSEcCtD
Riluzole—Dehydration—Docetaxel—head and neck cancer	0.000296	0.00247	CcSEcCtD
Riluzole—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000295	0.00246	CcSEcCtD
Riluzole—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000294	0.00246	CcSEcCtD
Riluzole—Liver function test abnormal—Docetaxel—head and neck cancer	0.000294	0.00245	CcSEcCtD
Riluzole—Skin disorder—Hydroxyurea—head and neck cancer	0.000292	0.00244	CcSEcCtD
Riluzole—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00029	0.00242	CcSEcCtD
Riluzole—Breast disorder—Docetaxel—head and neck cancer	0.000287	0.0024	CcSEcCtD
Riluzole—Anorexia—Hydroxyurea—head and neck cancer	0.000287	0.00239	CcSEcCtD
Riluzole—Decreased appetite—Vinblastine—head and neck cancer	0.000287	0.00239	CcSEcCtD
Riluzole—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000286	0.00239	CcSEcCtD
Riluzole—Constipation—Vinblastine—head and neck cancer	0.000282	0.00235	CcSEcCtD
Riluzole—Pain—Vinblastine—head and neck cancer	0.000282	0.00235	CcSEcCtD
Riluzole—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00028	0.00234	CcSEcCtD
Riluzole—Dysphagia—Docetaxel—head and neck cancer	0.000275	0.00229	CcSEcCtD
Riluzole—Arrhythmia—Fluorouracil—head and neck cancer	0.000272	0.00227	CcSEcCtD
Riluzole—Feeling abnormal—Vinblastine—head and neck cancer	0.000272	0.00227	CcSEcCtD
Riluzole—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00027	0.00225	CcSEcCtD
Riluzole—Alopecia—Fluorouracil—head and neck cancer	0.000269	0.00225	CcSEcCtD
Riluzole—Dyspnoea—Hydroxyurea—head and neck cancer	0.000268	0.00224	CcSEcCtD
Riluzole—Angina pectoris—Docetaxel—head and neck cancer	0.000268	0.00223	CcSEcCtD
Riluzole—Somnolence—Hydroxyurea—head and neck cancer	0.000267	0.00223	CcSEcCtD
Riluzole—Dyspepsia—Hydroxyurea—head and neck cancer	0.000265	0.00221	CcSEcCtD
Riluzole—Decreased appetite—Hydroxyurea—head and neck cancer	0.000261	0.00218	CcSEcCtD
Riluzole—Pancytopenia—Docetaxel—head and neck cancer	0.000261	0.00218	CcSEcCtD
Riluzole—Abdominal pain—Vinblastine—head and neck cancer	0.000261	0.00218	CcSEcCtD
Riluzole—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00026	0.00217	CcSEcCtD
Riluzole—Fatigue—Hydroxyurea—head and neck cancer	0.000259	0.00216	CcSEcCtD
Riluzole—Pain—Hydroxyurea—head and neck cancer	0.000257	0.00215	CcSEcCtD
Riluzole—Constipation—Hydroxyurea—head and neck cancer	0.000257	0.00215	CcSEcCtD
Riluzole—Neutropenia—Docetaxel—head and neck cancer	0.000257	0.00214	CcSEcCtD
Riluzole—Weight increased—Docetaxel—head and neck cancer	0.00025	0.00209	CcSEcCtD
Riluzole—Weight decreased—Docetaxel—head and neck cancer	0.000249	0.00207	CcSEcCtD
Riluzole—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000248	0.00207	CcSEcCtD
Riluzole—Pneumonia—Docetaxel—head and neck cancer	0.000246	0.00206	CcSEcCtD
Riluzole—Anaemia—Fluorouracil—head and neck cancer	0.000245	0.00205	CcSEcCtD
Riluzole—Infestation NOS—Docetaxel—head and neck cancer	0.000245	0.00204	CcSEcCtD
Riluzole—Infestation—Docetaxel—head and neck cancer	0.000245	0.00204	CcSEcCtD
Riluzole—Hypersensitivity—Vinblastine—head and neck cancer	0.000243	0.00203	CcSEcCtD
Riluzole—ABCG2—lymph node—head and neck cancer	0.000242	0.00757	CbGeAlD
Riluzole—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000242	0.00202	CcSEcCtD
Riluzole—Myocardial infarction—Docetaxel—head and neck cancer	0.00024	0.002	CcSEcCtD
Riluzole—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00024	0.002	CcSEcCtD
Riluzole—Stomatitis—Docetaxel—head and neck cancer	0.000239	0.00199	CcSEcCtD
Riluzole—Jaundice—Docetaxel—head and neck cancer	0.000239	0.00199	CcSEcCtD
Riluzole—Body temperature increased—Hydroxyurea—head and neck cancer	0.000238	0.00198	CcSEcCtD
Riluzole—Leukopenia—Fluorouracil—head and neck cancer	0.000237	0.00198	CcSEcCtD
Riluzole—Asthenia—Vinblastine—head and neck cancer	0.000237	0.00197	CcSEcCtD
Riluzole—ABCG2—Fluoropyrimidine Activity—XRCC3—head and neck cancer	0.000235	0.0581	CbGpPWpGaD
Riluzole—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000232	0.00193	CcSEcCtD
Riluzole—Epistaxis—Docetaxel—head and neck cancer	0.000231	0.00193	CcSEcCtD
Riluzole—CYP1A1—lymph node—head and neck cancer	0.00023	0.00719	CbGeAlD
Riluzole—Convulsion—Fluorouracil—head and neck cancer	0.00023	0.00192	CcSEcCtD
Riluzole—Agranulocytosis—Docetaxel—head and neck cancer	0.000229	0.00191	CcSEcCtD
Riluzole—Chest pain—Fluorouracil—head and neck cancer	0.000226	0.00188	CcSEcCtD
Riluzole—Myalgia—Fluorouracil—head and neck cancer	0.000226	0.00188	CcSEcCtD
Riluzole—Diarrhoea—Vinblastine—head and neck cancer	0.000226	0.00188	CcSEcCtD
Riluzole—Discomfort—Fluorouracil—head and neck cancer	0.000223	0.00186	CcSEcCtD
Riluzole—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000222	0.00185	CcSEcCtD
Riluzole—Haemoglobin—Docetaxel—head and neck cancer	0.000221	0.00184	CcSEcCtD
Riluzole—Rhinitis—Docetaxel—head and neck cancer	0.00022	0.00184	CcSEcCtD
Riluzole—Haemorrhage—Docetaxel—head and neck cancer	0.00022	0.00184	CcSEcCtD
Riluzole—Hepatitis—Docetaxel—head and neck cancer	0.00022	0.00184	CcSEcCtD
Riluzole—Hypoaesthesia—Docetaxel—head and neck cancer	0.000219	0.00183	CcSEcCtD
Riluzole—Confusional state—Fluorouracil—head and neck cancer	0.000218	0.00182	CcSEcCtD
Riluzole—Pharyngitis—Docetaxel—head and neck cancer	0.000218	0.00182	CcSEcCtD
Riluzole—Dizziness—Vinblastine—head and neck cancer	0.000218	0.00182	CcSEcCtD
Riluzole—Urinary tract disorder—Docetaxel—head and neck cancer	0.000217	0.00181	CcSEcCtD
Riluzole—Oedema peripheral—Docetaxel—head and neck cancer	0.000217	0.00181	CcSEcCtD
Riluzole—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000216	0.00181	CcSEcCtD
Riluzole—Oedema—Fluorouracil—head and neck cancer	0.000216	0.00181	CcSEcCtD
Riluzole—Connective tissue disorder—Docetaxel—head and neck cancer	0.000216	0.0018	CcSEcCtD
Riluzole—Asthenia—Hydroxyurea—head and neck cancer	0.000216	0.0018	CcSEcCtD
Riluzole—Urethral disorder—Docetaxel—head and neck cancer	0.000216	0.0018	CcSEcCtD
Riluzole—Infection—Fluorouracil—head and neck cancer	0.000215	0.00179	CcSEcCtD
Riluzole—Nervous system disorder—Fluorouracil—head and neck cancer	0.000212	0.00177	CcSEcCtD
Riluzole—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000212	0.00177	CcSEcCtD
Riluzole—Tachycardia—Fluorouracil—head and neck cancer	0.000211	0.00176	CcSEcCtD
Riluzole—Vomiting—Vinblastine—head and neck cancer	0.00021	0.00175	CcSEcCtD
Riluzole—Erythema multiforme—Docetaxel—head and neck cancer	0.000208	0.00174	CcSEcCtD
Riluzole—Headache—Vinblastine—head and neck cancer	0.000207	0.00172	CcSEcCtD
Riluzole—Anorexia—Fluorouracil—head and neck cancer	0.000206	0.00172	CcSEcCtD
Riluzole—Diarrhoea—Hydroxyurea—head and neck cancer	0.000206	0.00172	CcSEcCtD
Riluzole—Eye disorder—Docetaxel—head and neck cancer	0.000206	0.00172	CcSEcCtD
Riluzole—Cardiac disorder—Docetaxel—head and neck cancer	0.000204	0.0017	CcSEcCtD
Riluzole—Hypotension—Fluorouracil—head and neck cancer	0.000202	0.00169	CcSEcCtD
Riluzole—Angiopathy—Docetaxel—head and neck cancer	0.0002	0.00167	CcSEcCtD
Riluzole—Dizziness—Hydroxyurea—head and neck cancer	0.000199	0.00166	CcSEcCtD
Riluzole—Immune system disorder—Docetaxel—head and neck cancer	0.000199	0.00166	CcSEcCtD
Riluzole—Mediastinal disorder—Docetaxel—head and neck cancer	0.000198	0.00165	CcSEcCtD
Riluzole—Chills—Docetaxel—head and neck cancer	0.000197	0.00165	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000197	0.00165	CcSEcCtD
Riluzole—Arrhythmia—Docetaxel—head and neck cancer	0.000196	0.00164	CcSEcCtD
Riluzole—Nausea—Vinblastine—head and neck cancer	0.000196	0.00163	CcSEcCtD
Riluzole—Insomnia—Fluorouracil—head and neck cancer	0.000196	0.00163	CcSEcCtD
Riluzole—Paraesthesia—Fluorouracil—head and neck cancer	0.000194	0.00162	CcSEcCtD
Riluzole—Alopecia—Docetaxel—head and neck cancer	0.000194	0.00162	CcSEcCtD
Riluzole—Dyspnoea—Fluorouracil—head and neck cancer	0.000193	0.00161	CcSEcCtD
Riluzole—Mental disorder—Docetaxel—head and neck cancer	0.000193	0.00161	CcSEcCtD
Riluzole—Somnolence—Fluorouracil—head and neck cancer	0.000192	0.00161	CcSEcCtD
Riluzole—Malnutrition—Docetaxel—head and neck cancer	0.000191	0.0016	CcSEcCtD
Riluzole—Vomiting—Hydroxyurea—head and neck cancer	0.000191	0.0016	CcSEcCtD
Riluzole—Dyspepsia—Fluorouracil—head and neck cancer	0.000191	0.00159	CcSEcCtD
Riluzole—Rash—Hydroxyurea—head and neck cancer	0.00019	0.00158	CcSEcCtD
Riluzole—Dermatitis—Hydroxyurea—head and neck cancer	0.000189	0.00158	CcSEcCtD
Riluzole—Headache—Hydroxyurea—head and neck cancer	0.000188	0.00157	CcSEcCtD
Riluzole—Decreased appetite—Fluorouracil—head and neck cancer	0.000188	0.00157	CcSEcCtD
Riluzole—Dysgeusia—Docetaxel—head and neck cancer	0.000187	0.00156	CcSEcCtD
Riluzole—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000187	0.00156	CcSEcCtD
Riluzole—Back pain—Docetaxel—head and neck cancer	0.000185	0.00155	CcSEcCtD
Riluzole—Pain—Fluorouracil—head and neck cancer	0.000185	0.00154	CcSEcCtD
Riluzole—Muscle spasms—Docetaxel—head and neck cancer	0.000184	0.00154	CcSEcCtD
Riluzole—Nausea—Hydroxyurea—head and neck cancer	0.000179	0.00149	CcSEcCtD
Riluzole—Feeling abnormal—Fluorouracil—head and neck cancer	0.000178	0.00149	CcSEcCtD
Riluzole—Anaemia—Docetaxel—head and neck cancer	0.000177	0.00148	CcSEcCtD
Riluzole—Urticaria—Fluorouracil—head and neck cancer	0.000172	0.00144	CcSEcCtD
Riluzole—Syncope—Docetaxel—head and neck cancer	0.000172	0.00143	CcSEcCtD
Riluzole—Leukopenia—Docetaxel—head and neck cancer	0.000171	0.00143	CcSEcCtD
Riluzole—Body temperature increased—Fluorouracil—head and neck cancer	0.000171	0.00143	CcSEcCtD
Riluzole—Palpitations—Docetaxel—head and neck cancer	0.000169	0.00141	CcSEcCtD
Riluzole—Loss of consciousness—Docetaxel—head and neck cancer	0.000168	0.0014	CcSEcCtD
Riluzole—Cough—Docetaxel—head and neck cancer	0.000167	0.00139	CcSEcCtD
Riluzole—Convulsion—Docetaxel—head and neck cancer	0.000166	0.00138	CcSEcCtD
Riluzole—Hypertension—Docetaxel—head and neck cancer	0.000165	0.00138	CcSEcCtD
Riluzole—Chest pain—Docetaxel—head and neck cancer	0.000163	0.00136	CcSEcCtD
Riluzole—Arthralgia—Docetaxel—head and neck cancer	0.000163	0.00136	CcSEcCtD
Riluzole—Myalgia—Docetaxel—head and neck cancer	0.000163	0.00136	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000162	0.00135	CcSEcCtD
Riluzole—Hypersensitivity—Fluorouracil—head and neck cancer	0.00016	0.00133	CcSEcCtD
Riluzole—Dry mouth—Docetaxel—head and neck cancer	0.000159	0.00133	CcSEcCtD
Riluzole—SLC7A11—Transcriptional activation by NRF2—PIK3CA—head and neck cancer	0.000158	0.0391	CbGpPWpGaD
Riluzole—Confusional state—Docetaxel—head and neck cancer	0.000158	0.00131	CcSEcCtD
Riluzole—ABCG2—Fluoropyrimidine Activity—DPYD—head and neck cancer	0.000156	0.0386	CbGpPWpGaD
Riluzole—Oedema—Docetaxel—head and neck cancer	0.000156	0.0013	CcSEcCtD
Riluzole—Anaphylactic shock—Docetaxel—head and neck cancer	0.000156	0.0013	CcSEcCtD
Riluzole—Infection—Docetaxel—head and neck cancer	0.000155	0.0013	CcSEcCtD
Riluzole—Shock—Docetaxel—head and neck cancer	0.000154	0.00128	CcSEcCtD
Riluzole—Nervous system disorder—Docetaxel—head and neck cancer	0.000153	0.00128	CcSEcCtD
Riluzole—Pruritus—Fluorouracil—head and neck cancer	0.000153	0.00128	CcSEcCtD
Riluzole—Thrombocytopenia—Docetaxel—head and neck cancer	0.000153	0.00128	CcSEcCtD
Riluzole—Tachycardia—Docetaxel—head and neck cancer	0.000153	0.00127	CcSEcCtD
Riluzole—Skin disorder—Docetaxel—head and neck cancer	0.000152	0.00127	CcSEcCtD
Riluzole—Anorexia—Docetaxel—head and neck cancer	0.000149	0.00124	CcSEcCtD
Riluzole—Diarrhoea—Fluorouracil—head and neck cancer	0.000148	0.00124	CcSEcCtD
Riluzole—Hypotension—Docetaxel—head and neck cancer	0.000146	0.00122	CcSEcCtD
Riluzole—Dizziness—Fluorouracil—head and neck cancer	0.000143	0.00119	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000142	0.00119	CcSEcCtD
Riluzole—Insomnia—Docetaxel—head and neck cancer	0.000141	0.00118	CcSEcCtD
Riluzole—Paraesthesia—Docetaxel—head and neck cancer	0.00014	0.00117	CcSEcCtD
Riluzole—Dyspnoea—Docetaxel—head and neck cancer	0.000139	0.00116	CcSEcCtD
Riluzole—Somnolence—Docetaxel—head and neck cancer	0.000139	0.00116	CcSEcCtD
Riluzole—Vomiting—Fluorouracil—head and neck cancer	0.000138	0.00115	CcSEcCtD
Riluzole—Dyspepsia—Docetaxel—head and neck cancer	0.000138	0.00115	CcSEcCtD
Riluzole—Rash—Fluorouracil—head and neck cancer	0.000137	0.00114	CcSEcCtD
Riluzole—Dermatitis—Fluorouracil—head and neck cancer	0.000136	0.00114	CcSEcCtD
Riluzole—Decreased appetite—Docetaxel—head and neck cancer	0.000136	0.00113	CcSEcCtD
Riluzole—Headache—Fluorouracil—head and neck cancer	0.000136	0.00113	CcSEcCtD
Riluzole—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000135	0.00113	CcSEcCtD
Riluzole—Fatigue—Docetaxel—head and neck cancer	0.000135	0.00112	CcSEcCtD
Riluzole—Pain—Docetaxel—head and neck cancer	0.000134	0.00112	CcSEcCtD
Riluzole—Constipation—Docetaxel—head and neck cancer	0.000134	0.00112	CcSEcCtD
Riluzole—CYP1A2—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.000131	0.0325	CbGpPWpGaD
Riluzole—Feeling abnormal—Docetaxel—head and neck cancer	0.000129	0.00107	CcSEcCtD
Riluzole—Nausea—Fluorouracil—head and neck cancer	0.000129	0.00107	CcSEcCtD
Riluzole—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000128	0.00107	CcSEcCtD
Riluzole—SLC7A11—NRF2 pathway—TGFA—head and neck cancer	0.000127	0.0315	CbGpPWpGaD
Riluzole—Body temperature increased—Docetaxel—head and neck cancer	0.000124	0.00103	CcSEcCtD
Riluzole—Abdominal pain—Docetaxel—head and neck cancer	0.000124	0.00103	CcSEcCtD
Riluzole—Hypersensitivity—Docetaxel—head and neck cancer	0.000115	0.000961	CcSEcCtD
Riluzole—Asthenia—Docetaxel—head and neck cancer	0.000112	0.000936	CcSEcCtD
Riluzole—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000112	0.0277	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—SMUG1—head and neck cancer	0.000111	0.0275	CbGpPWpGaD
Riluzole—Pruritus—Docetaxel—head and neck cancer	0.000111	0.000923	CcSEcCtD
Riluzole—Diarrhoea—Docetaxel—head and neck cancer	0.000107	0.000892	CcSEcCtD
Riluzole—Dizziness—Docetaxel—head and neck cancer	0.000103	0.000862	CcSEcCtD
Riluzole—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000102	0.0252	CbGpPWpGaD
Riluzole—Vomiting—Docetaxel—head and neck cancer	9.93e-05	0.000829	CcSEcCtD
Riluzole—Rash—Docetaxel—head and neck cancer	9.85e-05	0.000822	CcSEcCtD
Riluzole—Dermatitis—Docetaxel—head and neck cancer	9.84e-05	0.000821	CcSEcCtD
Riluzole—Headache—Docetaxel—head and neck cancer	9.79e-05	0.000817	CcSEcCtD
Riluzole—CYP1A1—Estrogen metabolism—GSTM1—head and neck cancer	9.68e-05	0.0239	CbGpPWpGaD
Riluzole—Nausea—Docetaxel—head and neck cancer	9.28e-05	0.000775	CcSEcCtD
Riluzole—ABCG2—Fluoropyrimidine Activity—TYMS—head and neck cancer	8.91e-05	0.022	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen Receptor Pathway—CYP1A1—head and neck cancer	7.59e-05	0.0188	CbGpPWpGaD
Riluzole—SCN5A—Cardiac Progenitor Differentiation—NOTCH1—head and neck cancer	7.49e-05	0.0185	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—GSTM1—head and neck cancer	7.4e-05	0.0183	CbGpPWpGaD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	6.87e-05	0.017	CbGpPWpGaD
Riluzole—CYP1A1—Oxidative Stress—SOD2—head and neck cancer	6.46e-05	0.016	CbGpPWpGaD
Riluzole—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	6.43e-05	0.0159	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen metabolism—GSTM1—head and neck cancer	6.17e-05	0.0152	CbGpPWpGaD
Riluzole—CYP1A1—Oxidative Stress—GPX1—head and neck cancer	6.16e-05	0.0152	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—ATP7B—head and neck cancer	6.07e-05	0.015	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen metabolism—CYP1A1—head and neck cancer	5.85e-05	0.0145	CbGpPWpGaD
Riluzole—CYP1A1—Estrogen Receptor Pathway—STAT3—head and neck cancer	5.52e-05	0.0136	CbGpPWpGaD
Riluzole—CYP1A2—Xenobiotics—CYP1A1—head and neck cancer	5.38e-05	0.0133	CbGpPWpGaD
Riluzole—CYP1A2—Tamoxifen metabolism—CYP1A1—head and neck cancer	5.17e-05	0.0128	CbGpPWpGaD
Riluzole—CYP1A1—Arachidonic acid metabolism—GPX1—head and neck cancer	4.09e-05	0.0101	CbGpPWpGaD
Riluzole—CYP1A2—Melatonin metabolism and effects—CYP1A1—head and neck cancer	3.99e-05	0.00987	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—CEBPA—head and neck cancer	3.94e-05	0.00973	CbGpPWpGaD
Riluzole—CYP1A1—PPARA activates gene expression—YAP1—head and neck cancer	3.83e-05	0.00947	CbGpPWpGaD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—head and neck cancer	3.82e-05	0.00943	CbGpPWpGaD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—head and neck cancer	3.75e-05	0.00927	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen Receptor Pathway—STAT3—head and neck cancer	3.52e-05	0.0087	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—NAT2—head and neck cancer	3.51e-05	0.00867	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—PIK3CA—head and neck cancer	3.5e-05	0.00865	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—HRAS—head and neck cancer	3.24e-05	0.008	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—NAT2—head and neck cancer	3.22e-05	0.00796	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—NAT2—head and neck cancer	3.18e-05	0.00785	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—TP53—head and neck cancer	2.95e-05	0.0073	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	2.76e-05	0.00682	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	2.76e-05	0.00682	CbGpPWpGaD
Riluzole—CYP1A2—Tryptophan metabolism—CYP1A1—head and neck cancer	2.76e-05	0.00682	CbGpPWpGaD
Riluzole—CYP1A2—Arachidonic acid metabolism—GPX1—head and neck cancer	2.61e-05	0.00645	CbGpPWpGaD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—head and neck cancer	2.58e-05	0.00638	CbGpPWpGaD
Riluzole—CYP1A2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	2.58e-05	0.00638	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	2.58e-05	0.00636	CbGpPWpGaD
Riluzole—SCN5A—L1CAM interactions—MAPK3—head and neck cancer	2.58e-05	0.00636	CbGpPWpGaD
Riluzole—SCN5A—L1CAM interactions—MAPK1—head and neck cancer	2.45e-05	0.00605	CbGpPWpGaD
Riluzole—SCN5A—L1CAM interactions—EGFR—head and neck cancer	2.45e-05	0.00605	CbGpPWpGaD
Riluzole—CYP1A1—Arachidonic acid metabolism—PTGS2—head and neck cancer	2.41e-05	0.00595	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	2.39e-05	0.0059	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	2.25e-05	0.00555	CbGpPWpGaD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	2.23e-05	0.00552	CbGpPWpGaD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	2.2e-05	0.00544	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	2.2e-05	0.00543	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—NAT2—head and neck cancer	2.05e-05	0.00507	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	2.03e-05	0.00501	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—NAT2—head and neck cancer	2.03e-05	0.005	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—UROD—head and neck cancer	1.96e-05	0.00484	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	1.85e-05	0.00456	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	1.83e-05	0.00451	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	1.83e-05	0.00451	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	1.83e-05	0.00451	CbGpPWpGaD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	1.81e-05	0.00447	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—GSTM1—head and neck cancer	1.73e-05	0.00428	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	1.64e-05	0.00406	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—GSTM1—head and neck cancer	1.59e-05	0.00393	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—GSTM1—head and neck cancer	1.57e-05	0.00388	CbGpPWpGaD
Riluzole—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	1.54e-05	0.0038	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	1.52e-05	0.00376	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	1.47e-05	0.00362	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	1.43e-05	0.00354	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IL2—head and neck cancer	1.43e-05	0.00353	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—UROD—head and neck cancer	1.33e-05	0.00328	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	1.29e-05	0.0032	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—NOTCH1—head and neck cancer	1.26e-05	0.0031	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—VEGFA—head and neck cancer	1.22e-05	0.003	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	1.16e-05	0.00288	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	1.16e-05	0.00288	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	1.16e-05	0.00288	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—MAPK3—head and neck cancer	1.15e-05	0.00284	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—MAPK1—head and neck cancer	1.09e-05	0.0027	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	1.03e-05	0.00254	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—VEGFA—head and neck cancer	1.03e-05	0.00254	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	1.01e-05	0.00251	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	1e-05	0.00247	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—MAPK3—head and neck cancer	9.73e-06	0.0024	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	9.61e-06	0.00238	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—PIK3CA—head and neck cancer	9.49e-06	0.00235	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	9.48e-06	0.00234	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	9.35e-06	0.00231	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—MAPK1—head and neck cancer	9.26e-06	0.00229	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—EGFR—head and neck cancer	9.26e-06	0.00229	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—TP53—head and neck cancer	9.18e-06	0.00227	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—HRAS—head and neck cancer	8.78e-06	0.00217	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—UROD—head and neck cancer	8.46e-06	0.00209	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—NAT2—head and neck cancer	8.14e-06	0.00201	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—AKT1—head and neck cancer	7.75e-06	0.00192	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—HRAS—head and neck cancer	7.43e-06	0.00184	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—VEGFA—head and neck cancer	7.34e-06	0.00181	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—STAT3—head and neck cancer	7.27e-06	0.0018	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—DPYD—head and neck cancer	7.13e-06	0.00176	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MAPK3—head and neck cancer	6.94e-06	0.00172	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—YAP1—head and neck cancer	6.77e-06	0.00167	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MAPK1—head and neck cancer	6.61e-06	0.00163	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—EGFR—head and neck cancer	6.61e-06	0.00163	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	6.56e-06	0.00162	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.85e-06	0.00145	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—NAT2—head and neck cancer	5.51e-06	0.00136	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—HRAS—head and neck cancer	5.3e-06	0.00131	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—DPYD—head and neck cancer	4.83e-06	0.00119	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—AKT1—head and neck cancer	4.68e-06	0.00116	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—YAP1—head and neck cancer	4.58e-06	0.00113	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—TYMS—head and neck cancer	4.07e-06	0.001	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GSTM1—head and neck cancer	4.02e-06	0.000993	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GPX1—head and neck cancer	3.85e-06	0.000951	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP1A1—head and neck cancer	3.81e-06	0.000941	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.73e-06	0.000922	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.69e-06	0.000912	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NAT2—head and neck cancer	3.51e-06	0.000868	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.44e-06	0.000851	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—DPYD—head and neck cancer	3.08e-06	0.000761	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3e-06	0.000742	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—YAP1—head and neck cancer	2.92e-06	0.000722	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—TYMS—head and neck cancer	2.75e-06	0.00068	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GSTM1—head and neck cancer	2.72e-06	0.000672	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GPX1—head and neck cancer	2.61e-06	0.000644	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTGS2—head and neck cancer	2.27e-06	0.00056	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.2e-06	0.000542	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.12e-06	0.000523	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTEN—head and neck cancer	1.98e-06	0.000488	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.91e-06	0.000473	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—TYMS—head and neck cancer	1.75e-06	0.000434	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.73e-06	0.000429	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GPX1—head and neck cancer	1.66e-06	0.00041	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.64e-06	0.000406	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTGS2—head and neck cancer	1.53e-06	0.000379	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PIK3CA—head and neck cancer	1.39e-06	0.000344	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.35e-06	0.000334	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTEN—head and neck cancer	1.34e-06	0.00033	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—AKT1—head and neck cancer	1.14e-06	0.000281	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTGS2—head and neck cancer	9.78e-07	0.000242	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PIK3CA—head and neck cancer	9.44e-07	0.000233	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTEN—head and neck cancer	8.53e-07	0.000211	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—AKT1—head and neck cancer	7.71e-07	0.00019	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PIK3CA—head and neck cancer	6.02e-07	0.000149	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—AKT1—head and neck cancer	4.91e-07	0.000121	CbGpPWpGaD
